{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:30:21Z","timestamp":1792553421736,"version":"4.5.0"},"reference-count":266,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T00:00:00Z","timestamp":1621036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The psychedelic effects of some plants and fungi have been known and deliberately exploited by humans for thousands of years. Fungi, particularly mushrooms, are the principal source of naturally occurring psychedelics. The mushroom extract, psilocybin has historically been used as a psychedelic agent for religious and spiritual ceremonies, as well as a therapeutic option for neuropsychiatric conditions. Psychedelic use was largely associated with the \u201chippie\u201d counterculture movement, which, in turn, resulted in a growing, and still lingering, negative stigmatization for psychedelics. As a result, in 1970, the U.S. government rescheduled psychedelics as Schedule 1 drugs, ultimately ending scientific research on psychedelics. This prohibition on psychedelic drug research significantly delayed advances in medical knowledge on the therapeutic uses of agents such as psilocybin. A 2004 pilot study from the University of California, Los Angeles, exploring the potential of psilocybin treatment in patients with advanced-stage cancer managed to reignite interest and significantly renewed efforts in psilocybin research, heralding a new age in exploration for psychedelic therapy. Since then, significant advances have been made in characterizing the chemical properties of psilocybin as well as its therapeutic uses. This review will explore the potential of psilocybin in the treatment of neuropsychiatry-related conditions, examining recent advances as well as current research. This is not a systematic review.<\/jats:p>","DOI":"10.3390\/molecules26102948","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T23:17:16Z","timestamp":1621207036000},"page":"2948","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":222,"title":["The Therapeutic Potential of Psilocybin"],"prefix":"10.3390","volume":"26","author":[{"given":"Henry","family":"Lowe","sequence":"first","affiliation":[{"name":"Biotech R &amp; D Institute, University of the West Indies, Mona 99999, Jamaica"},{"name":"Vilotos Pharmaceuticals Inc., Baltimore, MD 21202, USA"},{"name":"Flavocure Biotech Inc., Baltimore, MD 21202, USA"},{"name":"Institute of Human Virology (IHV), University of Maryland School of Medicine, Baltimore, MD 21202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9683-6192","authenticated-orcid":false,"given":"Ngeh","family":"Toyang","sequence":"additional","affiliation":[{"name":"Vilotos Pharmaceuticals Inc., Baltimore, MD 21202, USA"},{"name":"Flavocure Biotech Inc., Baltimore, MD 21202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"Steele","sequence":"additional","affiliation":[{"name":"Biotech R &amp; D Institute, University of the West Indies, Mona 99999, Jamaica"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henkel","family":"Valentine","sequence":"additional","affiliation":[{"name":"Biotech R &amp; D Institute, University of the West Indies, Mona 99999, Jamaica"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Grant","sequence":"additional","affiliation":[{"name":"Biotech R &amp; D Institute, University of the West Indies, Mona 99999, Jamaica"},{"name":"The Psyence Group, Toronto, ON M5J 2J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amza","family":"Ali","sequence":"additional","affiliation":[{"name":"Biotech R &amp; D Institute, University of the West Indies, Mona 99999, Jamaica"},{"name":"The Psyence Group, Toronto, ON M5J 2J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfred","family":"Ngwa","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Gordon","sequence":"additional","affiliation":[{"name":"Caribbean School of Medical Sciences, Kingston 99999, Jamaica"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/070674370505000703","article-title":"Flashback: Psychiatric Experimentation with LSD in Historical Perspective","volume":"50","author":"Dyck","year":"2005","journal-title":"Can. J. Psychiatry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","article-title":"Potential Therapeutic Effects of Psilocybin","volume":"14","author":"Johnson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref_3","unstructured":"Buddy, T. (2021, March 23). The Types of Dissociative Drugs. Available online: https:\/\/www.verywellmind.com\/what-are-dissociative-drugs-63387."},{"key":"ref_4","unstructured":"NIDA (2021, March 23). What Are the Effects of Common Dissociative Drugs on the Brain and Body?, Available online: https:\/\/www.drugabuse.gov\/publications\/research-reports\/hallucinogens-dissociative-drugs\/what-are-effects-common-dissociative-drugs-brain-body."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addict. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/02791072.2015.1107664","article-title":"Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey","volume":"47","author":"Schindler","year":"2015","journal-title":"J. Psychoact. Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"key":"ref_8","first-page":"120","article-title":"A high-resolution in vivo atlas of the human brain\u2019s serotonin system","volume":"37","author":"Beliveau","year":"2017","journal-title":"J. Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Canal, C.E. (2018). Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action, New Psychoactive Substances; Springer Science and Business Media LLC.","DOI":"10.1007\/164_2018_107"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1021\/cr078224o","article-title":"Serotonin Receptors","volume":"108","author":"Nichols","year":"2008","journal-title":"Chem. Rev."},{"key":"ref_11","first-page":"157","article-title":"International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)","volume":"46","author":"Hoyer","year":"1994","journal-title":"Pharmacol. Rev."},{"key":"ref_12","first-page":"335","article-title":"Serotonin","volume":"6","author":"Frazer","year":"1999","journal-title":"Basic Neurochem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1177\/0269881115598338","article-title":"Psilocybin, psychological distress, and suicidality","volume":"29","author":"Hendricks","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Elflein, J. (2021, March 23). Psychedelic therapy\u2014Statistics & Facts. Available online: https:\/\/www.statista.com\/topics\/4277\/psychedelic-therapy\/.","DOI":"10.1007\/7854_2021_268"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zamaria, J.A. (2016). A Phenomenological Examination of Psilocybin and its Positive and Persisting Aftereffects. NeuroQuantology, 14.","DOI":"10.14704\/nq.2016.14.2.943"},{"key":"ref_16","unstructured":"Stafford, P. (2013). Psychedelics Encyclopedia, Third ed., Ronin Publishing."},{"key":"ref_17","unstructured":"WHO (2021, March 24). Mental Disorders. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/mental-disorders."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rehm, J., and Shield, K.D. (2019). Global Burden of Disease and the Impact of Mental and Addictive Disorders. Curr. Psychiatry Rep., 21.","DOI":"10.1007\/s11920-019-0997-0"},{"key":"ref_19","unstructured":"WHO (2021, March 24). World Mental Health Day: An Opportunity to Kick-Start a Massive scale-Up in Investment in Mental Health. Available online: https:\/\/www.who.int\/news\/item\/27-08-2020-world-mental-health-day-an-opportunity-to-kick-start-a-massive-scale-up-in-investment-in-mental-health."},{"key":"ref_20","unstructured":"Ritchie, H., and Roser, M. (2021, March 24). 2018. Mental Health. Available online: https:\/\/ourworldindata.org\/mental-health."},{"key":"ref_21","unstructured":"WHO (2021, March 24). Suicide. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/suicide."},{"key":"ref_22","unstructured":"PAHO (2021, March 24). COVID-19 Pandemic Exacerbates Suicide Risk Factors. Available online: https:\/\/www.paho.org\/en\/news\/10-9-2020-covid-19-pandemic-exacerbates-suicide-risk-factors."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cobeha.2016.10.009","article-title":"Tripping up addiction: The use of psychedelic drugs in the treatment of problematic drug and alcohol use","volume":"13","author":"Morgan","year":"2017","journal-title":"Curr. Opin. Behav. Sci."},{"key":"ref_25","first-page":"157","article-title":"Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction","volume":"7","author":"Griffiths","year":"2014","journal-title":"Curr. Drug Abuse Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.9740\/mhc.2017.01.024","article-title":"Clinical potential of psilocybin as a treatment for mental health conditions","volume":"7","author":"Daniel","year":"2017","journal-title":"Ment. Health Clin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1517\/13543784.2014.915312","article-title":"Drugs currently in Phase II clinical trials for cocaine addiction","volume":"23","author":"Kim","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0269881116684335","article-title":"An online survey of tobacco smoking cessation associated with naturalistic psychedelic use","volume":"31","author":"Johnson","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/02791072.2014.963754","article-title":"Psilocybin and Obsessive Compulsive Disorder","volume":"46","author":"Wilcox","year":"2014","journal-title":"J. Psychoact. Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot Study of Psilocybin Treatment for Anxiety in Patients with Advanced-Stage Cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/0269881116675783","article-title":"Psilocybin-assisted psychotherapy for dying cancer patients\u2014aiding the final trip","volume":"30","author":"Spiegel","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/0022167817715966","article-title":"Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress","volume":"57","author":"Swift","year":"2017","journal-title":"J. Humanist. Psychol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1177\/0269881116675764","article-title":"Psilocybin and palliative end-of-life care","volume":"30","author":"Shelton","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Malone, T.C., Mennenga, S.E., Guss, J., Podrebarac, S.K., Owens, L.T., Bossis, A.P., Belser, A.B., Agin-Liebes, G., Bogenschutz, M.P., and Ross, S. (2018). Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00256"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1177\/0269881117748902","article-title":"Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression","volume":"32","author":"Lyons","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study","volume":"3","author":"Bolstridge","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Beck, S. (2020). Psilocybin-Assisted Psychotherapy: Treating Depression and Anxiety with Mushrooms. Physician Assist. Stud. Stud. Artic., 7.","DOI":"10.33015\/dominican.edu\/2020.PAS.10"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Reynolds, C.F. (2020). Psilocybin-Assisted Supportive Psychotherapy in the Treatment of Major Depression\u2014Quo Vadis?. JAMA Psychiatry.","DOI":"10.1001\/jamapsychiatry.2020.2901"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Roseman, L., Nutt, D.J., and Carhart-Harris, R.L. (2018). Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00974"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Davis, A.K., Barrett, F.S., May, D.G., Cosimano, M.P., Sepeda, N.D., Johnson, M.W., Finan, P.H., and Griffiths, R.R. (2020). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry.","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zeifman, R.J., Wagner, A.C., Watts, R., Kettner, H., Mertens, L.J., and Carhart-Harris, R.L. (2020). Post-Psychedelic Reductions in Experiential Avoidance Are Associated with Decreases in Depression Severity and Suicidal Ideation. Front. Psychiatry, 11.","DOI":"10.3389\/fpsyt.2020.00782"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/01.wnl.0000219761.05466.43","article-title":"Response of cluster headache to psilocybin and LSD","volume":"66","author":"Sewell","year":"2006","journal-title":"Neurology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2217\/pmt-2017-0068","article-title":"Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: A potential role?","volume":"8","author":"Whelan","year":"2018","journal-title":"Pain Manag."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Nkadimeng, S.M., Nabatanzi, A., Steinmann, C.M.L., and Eloff, J.N. (2020). Phytochemical, Cytotoxicity, Antioxidant and Anti-Inflammatory Effects of Psilocybe Natalensis Magic Mushroom. Plants, 9.","DOI":"10.3390\/plants9091127"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/rapm-2020-101273","article-title":"Chronic pain and psychedelics: A review and proposed mechanism of action","volume":"45","author":"Castellanos","year":"2020","journal-title":"Reg. Anesth. Pain Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/13554794.2018.1468469","article-title":"Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF)","volume":"24","author":"Ramachandran","year":"2018","journal-title":"Neurocase"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Hendricks, P.S. (2020). Psilocybin-assisted group therapy: A new hope for demoralization. EClinicalMedicine, 27.","DOI":"10.1016\/j.eclinm.2020.100557"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Anderson, B.T., Danforth, A., Daroff, R., Stauffer, C., Ekman, E., Agin-Liebes, G., Trope, A., Boden, M.T., Dilley, J., and Mitchell, J. (2020). Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine, 27.","DOI":"10.1016\/j.eclinm.2020.100538"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/ijnp\/pyx047","article-title":"Effect of Psilocybin on Empathy and Moral Decision-Making","volume":"20","author":"Pokorny","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_55","first-page":"1","article-title":"Broadening Your Mind to Include Others: The relationship between serotonergic psychedelic experiences and maladaptive narcissism","volume":"237","author":"Patterson","year":"2020","journal-title":"Psychopharmacology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcbs.2019.11.001","article-title":"Exploring the case for research on incorporating psychedelics within interventions for borderline personality disorder","volume":"15","author":"Zeifman","year":"2020","journal-title":"J. Context. Behav. Sci."},{"key":"ref_57","unstructured":"Healy, M. (2021, April 26). Feeling rejected?. Mushrooms could help., Available online: https:\/\/www.latimes.com\/science\/sciencenow\/la-sci-social-rejection-psilocybin-mushrooms-20160418-story.html."},{"key":"ref_58","unstructured":"Dolan, E.W. (2021, April 26). Awe-inspiring psychedelic trips reduce narcissism by boosting connectedness and empathy, study suggests. Available online: https:\/\/www.psypost.org\/2020\/10\/awe-inspiring-psychedelic-trips-reduce-narcissism-by-boosting-connectedness-and-empathy-study-suggests-58277."},{"key":"ref_59","unstructured":"Lennon, A. (2021, March 24). Psychedelic Experiences Reduce Narcissistic Personality Traits. Available online: https:\/\/www.labroots.com\/trending\/neuroscience\/18989\/psychedelic-experiences-reduce-narcissistic-personality-traits."},{"key":"ref_60","unstructured":"Combstrong, A. (2021, March 24). Has Science Found a Cure for Narcissism?. Available online: https:\/\/medium.com\/happy-brain-club\/finally-a-cure-for-narcissism-b8d36d51a518."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/0013-4694(71)90072-1","article-title":"Effects of psilocybin, dimethyltryptamine, mescaline and various lysergic acid derivatives on the EEG and on photically induced epilepsy in the baboon (Papio papio)","volume":"31","author":"Meldrum","year":"1971","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1177\/0269881118771782","article-title":"Psychedelic use and intimate partner violence: The role of emotion regulation","volume":"32","author":"Thiessen","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_63","unstructured":"Inaba, D., and Cohen, W.E. (2014). Uppers, Downers, All Arounders: Physical and Mental Effects of Psychoactive Drugs, CNS Productions. [7th ed.]."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ijnp\/pyaa018","article-title":"Reviewing the Potential of Psychedelics for the Treatment of PTSD","volume":"23","author":"Krediet","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41429-020-0311-8","article-title":"Psilocybin: From ancient magic to modern medicine","volume":"73","author":"Nichols","year":"2020","journal-title":"J. Antibiot."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF01825267","article-title":"Ueber Pellote","volume":"40","author":"Heffter","year":"1898","journal-title":"Arch. Exp. Pathol. Pharmakol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.163.3864.245","article-title":"Hallucinogens of Plant Origin","volume":"163","author":"Schultes","year":"1969","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S2215-0366(15)00576-3","article-title":"Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA","volume":"3","author":"Mithoefer","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2307\/4110029","article-title":"Plants of the Gods: Origins of Hallucinogenic Use","volume":"35","author":"Brenan","year":"1980","journal-title":"Kew Bull."},{"key":"ref_70","first-page":"42","article-title":"Hallucinogenic drugs in pre-Columbian Mesoamerican cultures","volume":"30","year":"2015","journal-title":"Neurologia (Barcelona, Spain)"},{"key":"ref_71","unstructured":"Hofmann, A. (2009). LSD, My Problem Child: Reflections on Sacred Drugs, Mysticism, and Science, Multidisciplinary Association for Psychedelic Studies (MAPS). [4th ed.]."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1080\/02791072.2017.1320734","article-title":"Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders","volume":"49","author":"Thomas","year":"2017","journal-title":"J. Psychoact. Drugs"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0022-3999(64)90081-9","article-title":"Lysergic acid (LSD 25) and ritalin in the treatment of neurosis","volume":"8","author":"Davies","year":"1964","journal-title":"J. Psychosom. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1176\/ajp.126.4.481","article-title":"LSD in the Treatment of Alcoholism","volume":"126","author":"Johnson","year":"1969","journal-title":"Am. J. Psychiatry"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1176\/ajp.126.1.59","article-title":"A Clinical Study of LSD Treatment in Alcoholism","volume":"126","author":"Ludwig","year":"1969","journal-title":"Am. J. Psychiatry"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"333","DOI":"10.15288\/qjsa.1964.25.333","article-title":"The efficacy of LSD in the treatment of alcoholism","volume":"25","author":"Smart","year":"1964","journal-title":"Q. J. Stud. Alcohol"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0021-9681(71)90050-6","article-title":"LSD and alcoholism: A clinical study of treatment efficacy","volume":"24","author":"Visotsky","year":"1971","journal-title":"J. Chronic Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"589","DOI":"10.15288\/qjsa.1971.32.589","article-title":"Book Reviews\u2014LSD and alcoholism; a clinical study of treatment efficacy","volume":"32","author":"Jordy","year":"1971","journal-title":"Q. J. Stud. Alcohol"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/archpsyc.1968.01740100124021","article-title":"Lysergic Acid Diethylamide (LSD) in the Treatment of Alcoholism","volume":"19","author":"Dahlberg","year":"1968","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_80","first-page":"223","article-title":"A review of LSD treatment in alcoholism","volume":"6","author":"Abuzzahab","year":"1971","journal-title":"Int. Pharm."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1503\/cmaj.141358","article-title":"LSD: A new treatment emerging from the past","volume":"187","author":"Dyck","year":"2015","journal-title":"CMAJ Can. Med Assoc. J. J. l\u2019Association Med Can."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/BF02352266","article-title":"An evaluation of a maximum security therapeutic community for psychopaths and other mentally disordered offenders","volume":"16","author":"Rice","year":"1992","journal-title":"Law Hum. Behav."},{"key":"ref_83","first-page":"283","article-title":"Psychopaths: Is a therapeutic community therapeutic?","volume":"15","author":"Harris","year":"1994","journal-title":"Int. J. Ther. Supportive Organ."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.avb.2013.07.008","article-title":"Reducing psychopathic violence: A review of the treatment literature","volume":"18","author":"Reidy","year":"2013","journal-title":"Aggress. Violent Behav."},{"key":"ref_85","first-page":"170","article-title":"Treatment of autistic schizophrenic children with LSD-25 and UML-491","volume":"4","author":"Bender","year":"1961","journal-title":"Recent Adv. Biol. Psychiatry"},{"key":"ref_86","first-page":"43","article-title":"D-lysergic acid in the treatment of the biological features of childhood schizophrenia","volume":"7","author":"Bender","year":"1966","journal-title":"Dis. Nerv. Syst."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archpsyc.1962.01710210019003","article-title":"Autistic schizophrenic children. An experiment in the use of d-lysergic acid diethylamide (LSD-25)","volume":"6","author":"Freedman","year":"1962","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_88","first-page":"10","article-title":"The variable effects of LSD-25 on the behavior of a heterogeneous group of childhood schizophrenics","volume":"4","author":"Simmons","year":"1972","journal-title":"Behav. Neuropsychiatry"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/1520-6807(196407)1:3<297::AID-PITS2310010316>3.0.CO;2-T","article-title":"The treatment of childhood schizophrenia in a public school system","volume":"1","author":"Moller","year":"1964","journal-title":"Psychol. Sch."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/070674376100600407","article-title":"The Use of L.S.D. 25 (D-Lysergic Acid Diethylamide) in the Treatment of the Sexual Perversions","volume":"6","author":"Ball","year":"1961","journal-title":"Can. Psychiatr. Assoc. J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1176\/ajp.122.11.1201","article-title":"Modification of autistic behavior with LSD-25","volume":"122","author":"Simmons","year":"1966","journal-title":"Am. J. Psychiatry"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/13638490601106277","article-title":"Flashback to the 1960s: LSD in the treatment of autism","volume":"10","author":"Sigafoos","year":"2007","journal-title":"Dev. Neurorehabilit."},{"key":"ref_93","first-page":"303","article-title":"Temporal effects of LSD-25 and epinephrine on verbal behavior","volume":"70","author":"Honigfeld","year":"1964","journal-title":"PsycEXTRA Dataset"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF02159243","article-title":"Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen RauschpilzPsilocybe mexicana Heim","volume":"14","author":"Hofmann","year":"1958","journal-title":"Experientia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1037\/h0088612","article-title":"A new behavior change program using psilocybin","volume":"2","author":"Timothy","year":"1965","journal-title":"Psychotherapy"},{"key":"ref_96","first-page":"w14462","article-title":"Rehabilitation in patients with pulmonary arterial hypertension","volume":"147","author":"Keusch","year":"2017","journal-title":"Swiss Med. Week."},{"key":"ref_97","first-page":"29","article-title":"The effects of consciousness-expanding drugs on prisoner rehabilitation","volume":"10","author":"Leary","year":"1969","journal-title":"Psychedelic Rev."},{"key":"ref_98","first-page":"1","article-title":"Pahnke\u2019s \"Good Friday experiment\": A long-term follow-up and methodological critique","volume":"23","author":"Doblin","year":"1991","journal-title":"J. Transpers. Psychol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1021\/acsmedchemlett.0c00048","article-title":"Psilocybin Therapeutic Research: The Present and Future Paradigm","volume":"11","author":"Kargbo","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1176\/ajp.108.8.579","article-title":"Effects of mescaline and lysergic acid (d-LSD-25)","volume":"108","author":"Hoch","year":"1952","journal-title":"Am. J. Psychiatry"},{"key":"ref_101","unstructured":"Wong, S. (2021, March 25). Mind menders: How psychedelic drugs rebuild broken brains. Available online: https:\/\/www.newscientist.com\/article\/mg23631530-300-mind-menders-how-psychedelic-drugs-rebuild-broken-brains\/."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"key":"ref_103","unstructured":"(2021, April 27). Johns Hopkins Center for Psychedelic & Consciousness Research: Publications. Available online: https:\/\/hopkinspsychedelic.org\/publications."},{"key":"ref_104","unstructured":"Compass Pathways (2021, March 25). Treatment Resistant Depression & Clinical Trials: COMPASS. Available online: https:\/\/compasspathways.com\/our-research\/psilocybin-therapy\/clinical-trials\/treatment-resistant-depression\/."},{"key":"ref_105","first-page":"340","article-title":"Intranasal Esketamine (SpravatoTM) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant","volume":"44","author":"Bahr","year":"2019","journal-title":"P T Peer-Rev. J. Formul. Manag."},{"key":"ref_106","unstructured":"Business Wire (2021, March 25). FDA Grants Breakthrough Therapy Designation to Usona Institute\u2019s psilocybin program for major depressive disorder. Available online: https:\/\/www.businesswire.com\/news\/home\/20191122005452\/en\/FDA-grants-Breakthrough-Therapy-Designation-to-Usona-Institutes-psilocybin-program-for-major-depressive-disorder."},{"key":"ref_107","unstructured":"Stamets, P., and Weil, A. (1996). Psilocybin Mushrooms of the World: An Identification Guide, Ten Speed Press. [1st ed.]."},{"key":"ref_108","unstructured":"(2021, March 25). Johns Hopkins University. Available online: https:\/\/hopkinspsychedelic.org\/."},{"key":"ref_109","unstructured":"Newswire, P. (2021, March 25). Global Psychedelic Therapeutics Market, 2020-2030. Available online: https:\/\/www.prnewswire.com\/news-releases\/global-psychedelic-therapeutics-market-2020-2030-301148314.html."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Griffiths, R.R., Hurwitz, E.S., Davis, A.K., Johnson, M.W., and Jesse, R. (2019). Survey of subjective \u201cGod encounter experiences\u201d: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0214377"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/s41598-020-59282-y","article-title":"Emotions and brain function are altered up to one month after a single high dose of psilocybin","volume":"10","author":"Barrett","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Barrett, F.S., Krimmel, S.R., Griffiths, R.R., Seminowicz, D.A., and Mathur, B.N. (2020). Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. NeuroImage, 218.","DOI":"10.1016\/j.neuroimage.2020.116980"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s00213-020-05533-9","article-title":"Subjective features of the psilocybin experience that may account for its self-administration by humans: A double-blind comparison of psilocybin and dextromethorphan","volume":"237","author":"Carbonaro","year":"2020","journal-title":"Psychopharmacology"},{"key":"ref_114","unstructured":"Network Newswire (2021, March 25). Multi-Billion-Dollar Market Forecast in Psychedelic Therapeutics. Available online: https:\/\/www.networknewswire.com\/multi-billion-dollar-market-forecast-in-psychedelic-therapeutics\/."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0269881121991822","article-title":"Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches","volume":"35","author":"Barrett","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"ref_116","unstructured":"Usona Institute (2021, March 25). A Study of Psilocybin for Major Depressive Disorder (MDD); ClinicalTrials.gov Identifier: NCT03866174, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03866174."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","article-title":"Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis","volume":"16","author":"Vollenweider","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0893-133X(98)00089-X","article-title":"Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG","volume":"20","author":"Schreckenberger","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose?effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-007-0930-9","article-title":"Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans","volume":"195","author":"Carter","year":"2007","journal-title":"Psychopharmacology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0269881108094300","article-title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later","volume":"22","author":"Griffiths","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/02791072.1998.10399715","article-title":"Dr. Leary\u2019s Concord Prison Experiment: A 34-Year Follow-up Study","volume":"30","author":"Doblin","year":"1998","journal-title":"J. Psychoact. Drugs"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00005053-196312000-00007","article-title":"Reactions to psilocybjn administered in a supportive environment","volume":"137","author":"Leary","year":"1963","journal-title":"J. Nerv. Ment. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1177\/0269881116675781","article-title":"The role of psychedelics in palliative care reconsidered: A case for psilocybin","volume":"30","author":"Kelmendi","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Guss, J., Krause, R., and Sloshower, J. (2020). The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame). PsyArXiv.","DOI":"10.31234\/osf.io\/u6v9y"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Yale University (2021, March 25). Psilocybin for the Treatment of Cluster Headache, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02981173.","DOI":"10.1007\/s11916-021-00989-6"},{"key":"ref_127","unstructured":"Yale University (2021, March 25). Psilocybin\u2014Induced Neuroplasticity in the Treatment of Major Depressive Disorder. Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03554174."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Petranker, R., Kim, J., and Anderson, T. (2020). Microdosing as a response to the meaning crisis. PsyArXiv.","DOI":"10.31234\/osf.io\/2jnkf"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Petranker, R., Anderson, T., Maier, L.J., Barratt, M.J., A Ferris, J., and Winstock, A.R. (2020). Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention. J. Psychopharmacol.","DOI":"10.1177\/0269881120953994"},{"key":"ref_130","unstructured":"(2021, March 25). Psyence. Available online: https:\/\/www.psyence.com\/."},{"key":"ref_131","unstructured":"Rockefeller, A. (2021, March 26). Psilocybe cubensis (Earle) Singer (345579). Available online: https:\/\/mushroomobserver.org\/image\/show_image\/345579?obs=138685."},{"key":"ref_132","unstructured":"Alfonso, W. (2021, March 26). Psilocybe caerulescens Murrill. Available online: https:\/\/mushroomobserver.org\/417062?q=1aXNX."},{"key":"ref_133","unstructured":"Rockefeller, A. (2021, March 26). Psilocybe mexicana R. Heim. Available online: https:\/\/mushroomobserver.org\/168203?q=1aXOX."},{"key":"ref_134","unstructured":"Stewart, T. (2021, March 26). Psilocybe caerulipes (Peck) Sacc. Available online: https:\/\/mushroomobserver.org\/380223?q=1aTcf."},{"key":"ref_135","unstructured":"Rockefeller, A. (2021, March 26). Psilocybe stuntzii Guzm\u00e1n & J. Ott. Available online: https:\/\/mushroomobserver.org\/image\/show_image\/465307?obs=181566&q=1aXRI."},{"key":"ref_136","unstructured":"(2021, March 26). Psilocybe cyanescens Wakef. Available online: https:\/\/mushroomobserver.org\/440264?q=1aJM3."},{"key":"ref_137","unstructured":"Brown, C. (2021, March 26). Psilocybe azurescens Stamets & Gartz. Available online: https:\/\/mushroomobserver.org\/394045?q=1aM7H."},{"key":"ref_138","unstructured":"(2021, March 26). Psilocybe pelliculosa (A.H. Sm.) Singer & A.H. Available online: https:\/\/mushroomobserver.org\/439276?q=1aXUf."},{"key":"ref_139","unstructured":"(2021, March 26). Psilocybe tampanensis Guzm\u00e1n & Pollock. Available online: https:\/\/mushroomobserver.org\/140217?q=1aXVZ."},{"key":"ref_140","unstructured":"Brown, C. (2021, March 26). Psilocybe baeocystis Singer & A.H. Sm. Available online: https:\/\/mushroomobserver.org\/149218?q=1aXWC."},{"key":"ref_141","unstructured":"Rockefeller, A. (2021, March 26). Psilocybe hoogshagenii R. Heim 2017. Available online: https:\/\/mushroomobserver.org\/284430?q=1aXXY."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0031-6865(97)00014-9","article-title":"Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man","volume":"72","author":"Hasler","year":"1997","journal-title":"Pharm. Acta Helv."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","article-title":"Psilocybin Summary of knowledge and new perspectives","volume":"24","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_145","first-page":"270","article-title":"Some biochemical studies on psilocybin and psilogin","volume":"4","author":"Horita","year":"1963","journal-title":"J. Neuropsychiatr."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"8281","DOI":"10.1002\/chem.202000134","article-title":"Scalable Hybrid Synthetic\/Biocatalytic Route to Psilocybin","volume":"26","author":"Fricke","year":"2020","journal-title":"Chem. A Eur. J."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1055\/s-1999-3490","article-title":"Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin","volume":"1999","author":"Nichols","year":"1999","journal-title":"Synthesis"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00018-007-6362-1","article-title":"Enzymatic hydroxylation of aromatic compounds","volume":"64","author":"Ullrich","year":"2007","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_149","unstructured":"Londesbrough, D.J., Brown, C., Northen, J.S., Moore, G., Patil, H., and Nichols, D. (2019). Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their. (Number WO2019073379A1), Use. Patent."},{"key":"ref_150","unstructured":"Sliwoski, V. (2021, March 27). This Psilocybin Patent could be a Really Big Deal. Available online: https:\/\/harrisbricken.com\/cannalawblog\/this-psilocybin-patent-could-be-a-really-big-deal\/."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"12352","DOI":"10.1002\/anie.201705489","article-title":"Enzymatic Synthesis of Psilocybin","volume":"56","author":"Fricke","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ymben.2018.05.014","article-title":"Facile assembly and fluorescence-based screening method for heterologous expression of biosynthetic pathways in fungi","volume":"48","author":"Hoefgen","year":"2018","journal-title":"Metab. Eng."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ymben.2019.09.009","article-title":"In vivo production of psilocybin in E. coli","volume":"56","author":"Adams","year":"2019","journal-title":"Metab. Eng."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ymben.2019.12.007","article-title":"Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives","volume":"60","author":"Milne","year":"2020","journal-title":"Metab. Eng."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/biot.201300445","article-title":"Advances in metabolic engineering of yeast Saccharomyces cerevisiae for production of chemicals","volume":"9","author":"Borodina","year":"2014","journal-title":"Biotechnol. J."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Hassan, Z., Bosch, O.G., Singh, D., Narayanan, S., Kasinather, B.V., Seifritz, E., Kornhuber, J., Quednow, B.B., and M\u00fcller, C.P. (2017). Novel Psychoactive Substances\u2014Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs. Front. Psychiatry, 8.","DOI":"10.3389\/fpsyt.2017.00152"},{"key":"ref_157","first-page":"1","article-title":"Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines","volume":"2019","author":"Nava","year":"2019","journal-title":"Adv. Pharmacol. Sci."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/2045125316676092","article-title":"Role of psilocybin in the treatment of depression","volume":"7","author":"Mahapatra","year":"2017","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tins.2010.10.004","article-title":"Stuck in a rut: Rethinking depression and its treatment","volume":"34","author":"Holtzheimer","year":"2011","journal-title":"Trends Neurosci."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.euroneuro.2018.03.016","article-title":"Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination","volume":"28","author":"Grimm","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1002\/hbm.22562","article-title":"Enhanced repertoire of brain dynamical states during the psychedelic experience","volume":"35","author":"Tagliazucchi","year":"2014","journal-title":"Hum. Brain Mapp."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neuroimage.2019.05.060","article-title":"Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin","volume":"199","author":"Lord","year":"2019","journal-title":"NeuroImage"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/bs.pbr.2018.08.004","article-title":"Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens: Contributions of the resting brain","volume":"242","author":"Liechti","year":"2018","journal-title":"Prog. Brain Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1017\/S146114571000009X","article-title":"Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT1A receptors but not 5-HT2A receptors","volume":"13","author":"Bortolozzi","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_165","first-page":"203","article-title":"Psilocybin for treating substance use disorders?","volume":"17","author":"Schellekens","year":"2016","journal-title":"Expert Rev. Neurother."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Nagaeva, E., Zubarev, I., Gonzales, C.B., Forss, M., Nikouei, K., De Miguel, E., Elsil\u00e4, L., Linden, A.-M., Hjerling-Leffler, J., and Augustine, G.J. (2020). Heterogeneous somatostatin-expressing neuron population in mouse ventral tegmental area. eLife, 9.","DOI":"10.7554\/eLife.59328"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1472-8206.2004.00287.x","article-title":"Dopamine, depression and antidepressants","volume":"18","author":"Dailly","year":"2004","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0893-133X(98)00108-0","article-title":"5-HT Modulation of Dopamine Release in Basal Ganglia in Psilocybin-Induced Psychosis in Man\u2014A PET Study with [11C]raclopride","volume":"20","author":"Vollenweider","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jagp.2016.03.006","article-title":"Agitation in Alzheimer Disease as a Qualifying Condition for Medical Marijuana in the United States","volume":"24","author":"Maust","year":"2016","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Grandjean, J., Buehlmann, D., Buerge, M., Sigrist, H., Seifritz, E., Vollenweider, F.X., Pryce, C.R., and Rudin, M. (2021). Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice. NeuroImage, 225.","DOI":"10.1016\/j.neuroimage.2020.117456"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Erritzoe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1248\/bpb.b14-00315","article-title":"Effect of Psilocin on Extracellular Dopamine and Serotonin Levels in the Mesoaccumbens and Mesocortical Pathway in Awake Rats","volume":"38","author":"Sakashita","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/npp.2010.113","article-title":"Neuroanatomical and Neurochemical Substrates of Timing","volume":"36","author":"Coull","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2215-0366(20)30074-2","article-title":"Psychiatric symptoms abused by cannabis constituents: A systematic review and meta-analysis","volume":"7","author":"Hindley","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Carhart-Harris, R.L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J.N., Wall, M.B., Tanner, M., Kaelen, M., McGonigle, J., and Murphy, K. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-13282-7"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.08.003","article-title":"Lysergic Acid Diethylamide and Psilocybin Revisited","volume":"78","author":"Geyer","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","article-title":"Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers","volume":"78","author":"Kraehenmann","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.nicl.2015.08.009","article-title":"The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity","volume":"11","author":"Kraehenmann","year":"2016","journal-title":"Neuroimage Clin."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nrn2345","article-title":"Cognitive therapy versus medication for depression: Treatment outcomes and neural mechanisms","volume":"9","author":"DeRubeis","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_180","unstructured":"(2021, March 30). Magic Mushrooms and the Amygdala. Available online: https:\/\/www.neuroscientificallychallenged.com\/blog\/2014\/5\/12\/magic-mushrooms-and-the-amygdala."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/0269881119895520","article-title":"Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression","volume":"34","author":"Mertens","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00213-017-4754-y","article-title":"Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression","volume":"235","author":"Stroud","year":"2018","journal-title":"Psychopharmacol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/0024-3205(75)90118-6","article-title":"The dopamine receptor: Differential binding of d-LSD and related agents to agonist and antagonist states","volume":"17","author":"Creese","year":"1975","journal-title":"Life Sci."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Roseman, L., Leech, R., Feilding, A., Nutt, D.J., and Carhart-Harris, R.L. (2014). The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Front. Hum. Neurosci., 8.","DOI":"10.3389\/fnhum.2014.00204"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11682-015-9375-7","article-title":"Default mode network dissociation in depressive and anxiety states","volume":"10","author":"Coutinho","year":"2016","journal-title":"Brain Imaging Behav."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Carhart-Harris, R.L., Leech, R., Hellyer, P.J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D.R., and Nutt, D. (2014). The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Front. Hum. Neurosci., 8.","DOI":"10.3389\/fnhum.2014.00020"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1503\/jpn.120117","article-title":"Functional connectivity between the amygdala and prefrontal cortex in medication-naive individuals with major depressive disorder","volume":"38","author":"Kong","year":"2013","journal-title":"J. Psychiatry Neurosci."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12035-011-8214-0","article-title":"Serotonin and Prefrontal Cortex Function: Neurons, Networks, and Circuits","volume":"44","author":"Puig","year":"2011","journal-title":"Mol. Neurobiol."},{"key":"ref_189","unstructured":"Quetin, A. (1960). Psilocybin in clinical and experimental psychiatry. Impr. Modern."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00408109","article-title":"Comparison of the reactions induced by psilocybin and LSD-25 in man","volume":"1","author":"IIsbell","year":"1959","journal-title":"Psychopharmacol."},{"key":"ref_191","first-page":"42","article-title":"Clinical, biochemical and psychologic effects of psilocybin","volume":"130","author":"Hollister","year":"1961","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"James, E., Robertshaw, T.L., Hoskins, M., and Sessa, B. (2020). Psilocybin occasioned mystical-type experiences. Hum. Psychopharmacol. Clin. Exp., 35.","DOI":"10.1002\/hup.2742"},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Elsey, J.W. (2017). Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy. Drug Sci. Policy Law, 3.","DOI":"10.1177\/2050324517723232"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.euroneuro.2020.02.001","article-title":"A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding","volume":"33","author":"Madsen","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/acps.12904","article-title":"Effects of psilocybin therapy on personality structure","volume":"138","author":"Erritzoe","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_196","first-page":"520","article-title":"Patients\u2019 Accounts of Increased \u201cConnectedness\u201d and \u201cAcceptance\u201d After Psilocybin for Treatment-Resistant Depression","volume":"57","author":"Watts","year":"2017","journal-title":"J. Hum. Psychol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1177\/0269881117714049","article-title":"Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness","volume":"31","author":"Forstmann","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0269881117735685","article-title":"The relationships of classic psychedelic use with criminal behavior in the United States adult population","volume":"32","author":"Hendricks","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/0269881116642538","article-title":"Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use","volume":"30","author":"Walsh","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/0269881114565653","article-title":"Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population","volume":"29","author":"Hendricks","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/0269881111420188","article-title":"Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness","volume":"25","author":"MacLean","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/02791072.2017.1312643","article-title":"Psychedelics, Personality and Political Perspectives","volume":"49","author":"Nour","year":"2017","journal-title":"J. Psychoact. Drugs"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/jclp.20000","article-title":"The phenomenon of quantum change","volume":"60","author":"Miller","year":"2004","journal-title":"J. Clin. Psychol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-50612-3","article-title":"Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat","volume":"9","author":"Smigielski","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/dta.2950","article-title":"Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis","volume":"13","author":"Jurok","year":"2021","journal-title":"Drug Test. Anal."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/acs.jnatprod.9b01061","article-title":"Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin","volume":"83","author":"Sherwood","year":"2020","journal-title":"J. Nat. Prod."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/chem.201904363","article-title":"Simultaneous Production of Psilocybin and a Cocktail of \u03b2-Carboline Monoamine Oxidase Inhibitors in \u201cMagic\u201d Mushrooms","volume":"26","author":"Blei","year":"2020","journal-title":"Chemistry"},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Smith, W.R., and Sisti, D. (2020). Ethics and ego dissolution: The case of psilocybin. J. Med. Ethic.","DOI":"10.1136\/medethics-2020-106070"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jobm.3620290608","article-title":"Biotransformation of tryptamine derivatives in mycelial cultures ofPsilocybe","volume":"29","author":"Gartz","year":"1989","journal-title":"J. Basic Microbiol."},{"key":"ref_211","unstructured":"Bauer, B. (2021, March 31). Psilocybin Receives FDA Breakthrough Treatment Designation. Available online: https:\/\/psychedelicreview.com\/psilocybin-receives-fda-breakthrough-treatment-designation\/."},{"key":"ref_212","unstructured":"Bauer, B. (2021, March 31). The Top 10 Psilocybin Research Papers of 2020. Available online: https:\/\/psychedelicreview.com\/the-top-10-psilocybin-research-papers-of-2020\/."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1271\/bbb.90095","article-title":"Effects of Psilocybe argentipes on marble-burying behavior in mice","volume":"73","author":"Matsushima","year":"2009","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1055\/s-2006-962805","article-title":"Variation of the amount of Alkaloids in Fruit Bodies of Inocybe aeruginascens","volume":"53","author":"Gartz","year":"1987","journal-title":"Planta Med."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1055\/s-2006-931576","article-title":"Aeruginascin, a Trimethylammonium Analogue of Psilocybin from the Hallucinogenic Mushroom Inocybe aeruginascens","volume":"72","author":"Jensen","year":"2006","journal-title":"Planta Med."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"16940","DOI":"10.1021\/acsomega.0c02208","article-title":"Active Metabolite of Aeruginascin (4-Hydroxy-N,N,N-trimethyltryptamine): Synthesis, Structure, and Serotonergic Binding Affinity","volume":"5","author":"Chadeayne","year":"2020","journal-title":"ACS Omega"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/13880208909053954","article-title":"Analysis of Aeruginascin in Fruit Bodies of the Mushroom Inocybe aeruginascens","volume":"27","author":"Gartz","year":"1989","journal-title":"Int. J. Crude Drug Res."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/chem.201802758","article-title":"Production Options for Psilocybin: Making of the Magic","volume":"25","author":"Fricke","year":"2019","journal-title":"Chem. A Eur. J."},{"key":"ref_219","first-page":"21","article-title":"Factors affecting drug action","volume":"4","year":"1975","journal-title":"Aust. Nurses J."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1556\/2054.2018.001","article-title":"Inside bad trips: Exploring extra-pharmacological factors","volume":"2","author":"Ona","year":"2018","journal-title":"J. Psychedelic Stud."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jesp.2008.07.018","article-title":"A message in a bottle: Extrapharmacological effects of alcohol on aggression","volume":"45","author":"Subra","year":"2009","journal-title":"J. Exp. Soc. Psychol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neubiorev.2018.08.015","article-title":"Non-pharmacological factors that determine drug use and addiction","volume":"110","author":"Ahmed","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Haijen, E.C.H.M., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R.E., Hampshire, A.D.G., and Lorenz, R. (2018). Predicting Responses to Psychedelics: A Prospective Study. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00897"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00213-020-05464-5","article-title":"Tripping on nothing: Placebo psychedelics and contextual factors","volume":"237","author":"Olson","year":"2020","journal-title":"Psychopharmacology"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: Guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"ref_228","unstructured":"Davis, K. (2021, March 31). Psilocybin and Magic Mushrooms. Available online: https:\/\/www.medicalnewstoday.com\/articles\/308850#effects."},{"key":"ref_229","unstructured":"Hartney, E. (2020, April 10). Magic mushrooms: Everything You\u2019ve been Afraid to Ask. Available online: https:\/\/www.verywellmind.com\/what-are-magic-mushrooms-22085."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/096032718200100408","article-title":"The Problem of Psilocybin Mushroom Abuse","volume":"1","author":"Peden","year":"1982","journal-title":"Hum. Toxicol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1192\/bjp.132.6.602","article-title":"Abuse of Indigenous Psilocybin Mushrooms: A New Fashion and Some Psychiatric Complications","volume":"132","author":"Hyde","year":"1978","journal-title":"Br. J. Psychiatry"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"NeuroReport"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.yrtph.2011.01.006","article-title":"Harm potential of magic mushroom use: A review","volume":"59","author":"Opperhuizen","year":"2011","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_234","unstructured":"Mitrokostas, S. (2020, April 10). 10 potential risks of taking \u2018MAGIC\u2019 MUSHROOMS. Available online: https:\/\/www.insider.com\/are-magic-mushrooms-dangerous-2019-1."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5941\/MYCO.2014.42.3.215","article-title":"Toxicological Profiles of Poisonous, Edible, and Medicinal Mushrooms","volume":"42","author":"Jo","year":"2014","journal-title":"Mycobiology"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/17512433.2018.1511424","article-title":"Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: A systematic review of systematic reviews","volume":"11","author":"Bouso","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/00952999309001618","article-title":"Toward a Comparative Overview of Dependence Potential and Acute Toxicity of Psychoactive Substances Used Nonmedically","volume":"19","author":"Gable","year":"1993","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1360-0443.2004.00744.x","article-title":"Comparison of acute lethal toxicity of commonly abused psychoactive substances","volume":"99","author":"Gable","year":"2004","journal-title":"Addiction"},{"key":"ref_239","unstructured":"Yirka, B. (2021, April 27). Phase 1 clinical trials for Psilocybin show no adverse effects. Available online: https:\/\/medicalxpress.com\/news\/2019-12-phase-clinical-trials-psilocybin-adverse.html."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00008877-200403000-00007","article-title":"Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys","volume":"15","author":"Fantegrossi","year":"2004","journal-title":"Behav. Pharmacol."},{"key":"ref_241","unstructured":"(2021, April 17). How risky are Psilocybin Mushrooms Compared to other Drugs?. Available online: https:\/\/drugpolicy.org\/drug-facts\/how-risky-are-psilocybin-mushrooms."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/j.1445-5994.2012.02955.x","article-title":"A fatal case of \u2018magic mushroom\u2019 ingestion in a heart transplant recipient","volume":"42","author":"Lim","year":"2012","journal-title":"Intern. Med. J."},{"key":"ref_244","first-page":"193","article-title":"Suizid unter Psilocin-Einfluss [Suicide under the influence of \u201cmagic mushrooms\u201d]","volume":"231","year":"2013","journal-title":"Arch. Kriminol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1089\/jpm.2017.0684","article-title":"Taking Psychedelics Seriously","volume":"21","author":"Byock","year":"2018","journal-title":"J. Palliat. Med."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00401404","article-title":"Tolerance and cross-tolerance among psychotomimetic drugs","volume":"13","author":"Appel","year":"1968","journal-title":"Psychopharmacol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The Pharmacology of Lysergic Acid Diethylamide: A Review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"ref_248","unstructured":"Strassman, R. (2008). Inner Paths to Outer Space: Journeys to Alien Worlds through Psychedelics and Other Spiritual Technologies, Paperback Edition; Park Street Press."},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Freye, E. (2009). The Mushroom Psilocybin with Psychedelic Properties. Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs, Springer Science and Business Media LLC.","DOI":"10.1007\/978-90-481-2448-0"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1511\/2006.59.206","article-title":"The Toxicity of Recreational Drugs","volume":"94","author":"Gable","year":"2006","journal-title":"Am. Sci."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0731-7085(02)00278-9","article-title":"Renal excretion profiles of psilocin following oral administration of psilocybin: A controlled study in man","volume":"30","author":"Hasler","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","article-title":"Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults","volume":"56","author":"Brown","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11419-006-0006-2","article-title":"Direct detection of serum psilocin glucuronide by LC\/MS and LC\/MS\/MS: Time-courses of total and free (unconjugated) psilocin concentrations in serum specimens of a \u201cmagic mushroom\u201d user","volume":"24","author":"Kamata","year":"2006","journal-title":"Forensic Toxicol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/dta.244","article-title":"Enzyme-assisted synthesis of the glucuronide conjugate of psilocin, an hallucinogenic component of magic mushrooms","volume":"3","author":"Shoda","year":"2011","journal-title":"Drug Test. Anal."},{"key":"ref_255","unstructured":"Alexandrov, N. (2020, April 10). 2020 Psychedelics Industry Insights Report. Available online: https:\/\/stockhouse.com\/news\/newswire\/2020\/01\/17\/2020-psychedelics-industry-insights-report."},{"key":"ref_256","unstructured":"(2020, April 10). Numinus Completes First Extraction of its Psilocybe Mushrooms. Available online: https:\/\/psilocybinalpha.com\/news\/numinus-completes-first-extraction-of-its-psilocybe-mushrooms."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future","volume":"42","author":"Goodwin","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"ref_258","unstructured":"Hirschfeld, A. (2020, April 10). Why Magic Mushrooms are the Next Big Booming (and Legal!) Drug Market. Available online: https:\/\/observer.com\/2020\/10\/why-magic-mushrooms-are-the-next-big-booming-and-legal-drug-market\/."},{"key":"ref_259","unstructured":"Segreaves, M., and Smith, C. (2020, April 15). Effort to Decriminalize Psychedelic Mushrooms Moves Closer to Place on November Ballot. Available online: https:\/\/www.nbcwashington.com\/news\/local\/effort-to-decriminalize-psychedelic-mushrooms-moves-closer-to-place-on-november-ballot\/2210420\/."},{"key":"ref_260","unstructured":"Moyer, J.D.C. (2020, April 15). Voters Approve Ballot Question to Decriminalize Psychedelic Mushrooms. Available online: https:\/\/www.washingtonpost.com\/local\/dc-politics\/dc-magic-mushrooms-result\/2020\/11\/03\/bb929e86-1abc-11eb-bb35-2dcfdab0a345_story.html."},{"key":"ref_261","unstructured":"News, K. (2020, April 15). Oregon becomes first state to legalize \u2018magic\u2019 mushrooms. Available online: https:\/\/www.valleycentral.com\/news\/national-news\/oregon-becomes-first-state-to-legalize-magic-mushrooms\/."},{"key":"ref_262","unstructured":"Acker, L. (2020, April 15). Oregon becomes First State to Legalize Psychedelic Mushrooms. Available online: https:\/\/www.oregonlive.com\/politics\/2020\/11\/oregon-becomes-first-state-to-legalize-psychedelic-mushrooms.html."},{"key":"ref_263","unstructured":"Leonhardt, M. (2020, April 15). Here\u2019s How much \u2018Magic Mushroom Retreats\u2019 Like Goop Lab\u2019s Actually Cost. Available online: https:\/\/www.cnbc.com\/2020\/01\/24\/heres-how-much-magic-mushroom-retreats-like-goop-labs-actually-cost.html."},{"key":"ref_264","unstructured":"Berger, M. (2020, April 15). Cybin Corp\u2019s Clinical Trials in Jamaica Are Setting The Company Up For A Quicker Route To Market Than Their Peers. Available online: https:\/\/mushroomstocks.com\/cannabis-article\/cybin-corps-clinical-trials-in-jamaica-are-setting-the-company-up-for-a-quicker-route-to-market-than-their-peers\/."},{"key":"ref_265","unstructured":"K\u00fc\u00e7\u00fcksen, M., and K\u00fc\u00e7\u00fcksen, A.N. (2020). Psilocybin and\/or psilocin in combination with cannabinoids and\/or terpenes. (No. US10729706B2), U.S. Patent."},{"key":"ref_266","unstructured":"Bauer, B. (2020, April 15). The Miller School of Medicine is Studying CBD + Psilocybin for Treating Traumatic Brain Injury and PTSD. Available online: https:\/\/psychedelicreview.com\/the-miller-school-of-medicine-is-studying-cbd-psilocybin-for-treating-traumatic-brain-injury-and-ptsd\/."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/10\/2948\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:02:02Z","timestamp":1760162522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/10\/2948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,15]]},"references-count":266,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["molecules26102948"],"URL":"https:\/\/doi.org\/10.3390\/molecules26102948","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,15]]}}}